JP2024521164A5 - - Google Patents
Info
- Publication number
- JP2024521164A5 JP2024521164A5 JP2023572868A JP2023572868A JP2024521164A5 JP 2024521164 A5 JP2024521164 A5 JP 2024521164A5 JP 2023572868 A JP2023572868 A JP 2023572868A JP 2023572868 A JP2023572868 A JP 2023572868A JP 2024521164 A5 JP2024521164 A5 JP 2024521164A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- day
- teprizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192414P | 2021-05-24 | 2021-05-24 | |
| US63/192,414 | 2021-05-24 | ||
| PCT/US2022/030780 WO2022251258A1 (en) | 2021-05-24 | 2022-05-24 | Methods for treating post infectious autoimmune diabetes |
| US17/752,650 | 2022-05-24 | ||
| US17/752,650 US20220372146A1 (en) | 2021-05-24 | 2022-05-24 | Methods for treating post infectious autoimmune diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521164A JP2024521164A (ja) | 2024-05-28 |
| JP2024521164A5 true JP2024521164A5 (https=) | 2025-11-05 |
Family
ID=84104472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572868A Pending JP2024521164A (ja) | 2021-05-24 | 2022-05-24 | 感染後自己免疫性糖尿病を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220372146A1 (https=) |
| EP (1) | EP4347021A4 (https=) |
| JP (1) | JP2024521164A (https=) |
| KR (1) | KR20240023522A (https=) |
| CN (1) | CN117794572A (https=) |
| AU (1) | AU2022283272A1 (https=) |
| CA (1) | CA3219473A1 (https=) |
| IL (1) | IL308627A (https=) |
| MX (1) | MX2023013849A (https=) |
| WO (1) | WO2022251258A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4532552A4 (en) * | 2022-05-24 | 2025-10-22 | Provention Bio Inc | METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES |
| TW202506177A (zh) * | 2023-03-30 | 2025-02-16 | 美商普泛森生技公司 | 減少外源性胰島素使用之方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| SG177907A1 (en) * | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| WO2015073833A1 (en) * | 2013-11-15 | 2015-05-21 | Pharmacyclics, Inc. | Methods for delaying or preventing the onset of type 1 diabetes |
| WO2020232247A1 (en) * | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3148179A1 (en) * | 2019-08-20 | 2021-02-25 | Bruce J. Mccreedy Jr. | Lymphodepletion dosing regimens for cellular immunotherapies |
| IL298999A (en) * | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) * | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4532552A4 (en) * | 2022-05-24 | 2025-10-22 | Provention Bio Inc | METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES |
-
2022
- 2022-05-24 KR KR1020237043749A patent/KR20240023522A/ko active Pending
- 2022-05-24 JP JP2023572868A patent/JP2024521164A/ja active Pending
- 2022-05-24 US US17/752,650 patent/US20220372146A1/en not_active Abandoned
- 2022-05-24 IL IL308627A patent/IL308627A/en unknown
- 2022-05-24 WO PCT/US2022/030780 patent/WO2022251258A1/en not_active Ceased
- 2022-05-24 MX MX2023013849A patent/MX2023013849A/es unknown
- 2022-05-24 CA CA3219473A patent/CA3219473A1/en active Pending
- 2022-05-24 CN CN202280044277.7A patent/CN117794572A/zh active Pending
- 2022-05-24 EP EP22812013.5A patent/EP4347021A4/en active Pending
- 2022-05-24 AU AU2022283272A patent/AU2022283272A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521164A5 (https=) | ||
| Kitabchi et al. | The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis | |
| Jones et al. | Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes | |
| Schmeltz et al. | Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia | |
| Inagaki et al. | Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52‐week open‐label study | |
| JP6367115B2 (ja) | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 | |
| Meneghini | Early insulin treatment in type 2 diabetes: what are the pros? | |
| Frandsen et al. | Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo‐controlled, double‐blind, parallel‐group study | |
| JP2024520444A5 (https=) | ||
| CN105142661B (zh) | 通过长效胰岛素制剂治疗糖尿病 | |
| CN103648520A (zh) | 用于诱导ii型糖尿病患者体重减轻或者/和用于防止ii型糖尿病患者体重增加的药物组合产品 | |
| JP2014514356A (ja) | ２型糖尿病の処置のためのリキシセナチド及びメトホルミン | |
| CN103582491A (zh) | 2型糖尿病患者中低血糖症的预防 | |
| US20240245656A1 (en) | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs | |
| Lim et al. | Effect of the concomitant use of subcutaneous basal insulin and intravenous insulin infusion in the treatment of severe hyperglycemic patients | |
| Sprunt et al. | Some aspects of the pharmacology of metyrapone | |
| Frias et al. | A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections | |
| MX2011004189A (es) | Uso de cloruro de amonio en terapia. | |
| Shrestha et al. | Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes | |
| Yuan et al. | Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes | |
| Akizawa et al. | Dose‐finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double‐blind, randomized, placebo‐controlled and sevelamer hydrochloride‐controlled open‐label, parallel group study | |
| Ray et al. | Efficacy and safety of oral semaglutide in managing type 2 diabetes in India: A real-world study | |
| WO2016001185A1 (en) | Dosage regimen for the treatment of diabetes | |
| Ganda | Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes | |
| Gao et al. | Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study |